Tonix Pharmaceuticals Expands Commercial Access for TONMYA® as Investors Monitor Market Data
Greetings Readers,
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a commercial-stage biotechnology company, recently announced an important access milestone for TONMYA®, its FDA-approved treatment for fibromyalgia in adults.
According to the company, Tonix entered into an agreement with a leading group purchasing organization that provides coverage for approximately 35 million U.S. commercial lives. This represents roughly 20% of the estimated 177 million commercial lives in the United States, with the agreement effective May 1, 2026.
TONMYA is commercially launched and is described by Tonix as the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years. The company also describes TONMYA as a first-in-class, non-opioid analgesic intended as a daily bedtime medicine for long-term use.
Fibromyalgia remains a large chronic pain market, affecting more than 10 million adults in the U.S., with symptoms that may include chronic widespread pain, nonrestorative sleep, fatigue, morning stiffness, cognitive difficulties, anxiety, and depression. Tonix has also reported that TONMYA is currently covered under Medicaid in 37 states, representing approximately 52 million lives.
From a public-market perspective, TNXP has also remained on the radar of investors monitoring small-cap biotechnology names. Recent market data shows the stock trading materially below its reported 52-week high of $69.97, with a reported 52-week low of $11.60. As of May 5, 2026, TNXP was recently quoted around $13.23 during the trading session.
Key items investors may want to monitor
- Commercial access: TONMYA now has commercial payer coverage tied to approximately 35 million U.S. commercial lives.
- Medicaid coverage: Tonix reported coverage in 37 states, representing approximately 52 million Medicaid lives.
- Market size: Fibromyalgia affects more than 10 million U.S. adults, according to the company.
- 52-week range: Public market data shows a 52-week range of approximately $11.60 to $69.97.
For investors following Tonix, the central focus remains commercial execution: payer access, reimbursement expansion, patient adoption, and the company’s ability to build TONMYA within the fibromyalgia treatment market.
IMPORTANT DISCLOSURE – PAID SPONSORSHIP
This communication is a paid advertisement and is provided for informational and marketing purposes only. Magnify 432 (“Publisher”) has been compensated $150,000 USD in cash by Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to disseminate promotional content regarding the company for a period of one (1) week beginning on 5/6/26 (the “Term”). Compensation consists solely of cash and does not include any stock, options, warrants, or any other securities or financial instruments.
Because the Publisher receives monetary compensation for this communication, this creates a material conflict of interest. This content should be viewed strictly as a commercial advertisement and not as independent research, analyst commentary, or investment advice.
Nothing contained herein constitutes investment advice, financial advice, or a recommendation to buy, sell, or hold any security. Information contained herein has been obtained from publicly available sources believed to be reliable, including recent company press releases, but has not been independently verified by the Publisher, and the Publisher makes no representation or warranty as to its accuracy or completeness. All opinions or views expressed are subject to change without notice.
Investing in micro-cap and small-cap securities is highly speculative and involves substantial risk, including the possible loss of principal. Securities of this nature may be highly volatile, illiquid, and subject to significant market manipulation, promotional activity, and sudden price swings. Past performance is not indicative of future results.
The Publisher does not currently hold any position in the securities of Tonix Pharmaceuticals Holding Corp. and has not received any stock, options, warrants, or any other securities or financial instruments as compensation for this advertisement.
This advertisement is not tailored to any individual’s investment objectives, financial situation, or needs. Readers should conduct their own due diligence, review all publicly available filings and disclosures of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), including those filed with the U.S. Securities and Exchange Commission (SEC), Nasdaq, and other applicable regulatory platforms, and consult with a licensed financial advisor before making any investment decision.
By reading this communication, you acknowledge and agree that you are viewing paid promotional content and that any investment decision you make is solely your own responsibility.
Ben | 12 Honister Gardens | Harrow, HA7 2EH GB